FIELD: biotechnology.
SUBSTANCE: antibody that specifically binds to human C5, a method for the treatment of a disease or a disorder mediated with complement paths in an individual, including a stage of injection to the specified individual of an anti-C5 antibody, a method for the reduction in complement system activity in an individual, an expression vector, and a cell for antibody production are presented.
EFFECT: invention allows for effective treatment of complement-mediated disorder in an individual by inhibiting the complement signal transmission using an anti-C5 antibody, by means of bringing into contact the individual with the anti-C5 antibody.
39 cl, 33 dwg, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMANIZED ANTI-C5 ANTIBODIES AND THEIR APPLICATION | 2019 |
|
RU2792237C2 |
| ANTI-C5a ANTIBODIES AND THEIR APPLICATIONS | 2018 |
|
RU2773779C2 |
| ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS | 2013 |
|
RU2698131C2 |
| ANTIBODIES TO SURFACE DETERMINANTS OF S. AUREUS | 2013 |
|
RU2808018C2 |
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| MONOCLONAL ANTIBODIES AGAINST HUMAN TIM-3 | 2019 |
|
RU2777336C1 |
| NOVEL MONOCLONAL ANTIBODIES TO LAM AND PIM6/LAM FOR DIAGNOSING AND TREATING INFECTIONS CAUSED BY MYCOBACTERIUM TUBERCULOSIS | 2017 |
|
RU2732502C2 |
| ANTIBODIES SPECIFIC TO HUMAN POLIOVIRUS RECEPTOR (PVR) | 2017 |
|
RU2756275C2 |
| MONOCLONAL ANTIBODIES TO INTERLEUKIN-31 FOR VETERINARY USE | 2019 |
|
RU2795411C2 |
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
